{
    "code": "60001172",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001172",
    "time": "2023-11-16 23:06:21",
    "許可證字號": "衛部菌疫輸字第001172號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "115\/09\/22",
    "發證\/登錄日期": "110\/09\/22",
    "許可證\/登錄種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA06000117200",
    "中文品名": "賀雙妥皮下注射劑 1200\/600毫克",
    "英文品名": "Phesgo Solution for Subcutaneous Injection 1200\/600 mg",
    "適應症": "早期乳癌 (EBC)\r\n與化學治療藥物合併使用於：\r\n˙術前輔助療法適用於HER2陽性，局部晚期、發炎性或早期乳癌(腫瘤直徑大於2 cm或淋巴結陽性)之病人，作為早期乳癌完整治療處方之一部分。\r\n˙術後輔助治療適用於HER2陽性且具有高復發風險之早期乳癌病人。\r\n轉移性乳癌(MBC)\r\n與docetaxel併用於治療轉移後未曾以抗HER2或化學療法治療之HER2陽性轉移性乳癌病人。",
    "劑型": "220皮下注射劑",
    "包裝": "玻璃小瓶裝；100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "基因工程產品_新複方;",
    "監視期限": "115\/09\/22",
    "主成分略述": "Pertuzumab, Trastuzumab",
    "限制項目": "02輸　入",
    "申請商名稱": "羅氏大藥廠股份有限公司",
    "申請商地址": "台北市信義區松仁路100號40樓、40樓之1、41樓之1",
    "主製造廠": [
        {
            "製造廠名稱": "F. HOFFMANN-LA ROCHE LTD.",
            "製造廠廠址": "WURMISWEG, CH-4303 KAISERAUGST, SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "ROCHE DIAGNOSTICS GMBH",
            "製造廠廠址": "NONNENWALD 2, D-82377 PENZBERG, GERMANY",
            "製造廠公司地址": "",
            "製造廠國別": "GERMANY",
            "製程": "原料藥製造廠"
        },
        {
            "製造廠名稱": "Roche Singapore Technical Operations Pte.Ltd.",
            "製造廠廠址": "10 Tuas Bay Link, 637394 Singapore",
            "製造廠公司地址": "",
            "製造廠國別": "SINGAPORE",
            "製程": "原料藥製造廠"
        },
        {
            "製造廠名稱": "GENENTECH, INC.",
            "製造廠廠址": "1000 NEW HORIZONS WAY, VACAVILLE, CA 95688, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "原料藥製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013003800",
            "成分名稱": "Pertuzumab",
            "含量描述": "",
            "含量": "1200.0000000000",
            "單位": "MG"
        },
        {
            "成分類別": "主成分",
            "成分代碼": "1013004800",
            "成分名稱": "Trastuzumab",
            "含量描述": "",
            "含量": "600.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Phesgo賀雙妥-中文仿單 CDS 3.0_0921-PHE-01_450x500mm_排-110-10-27.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001172&Seq=001&Type=9"
        },
        {
            "title": "Phesgo賀雙妥 LD_瓶標1200-600_001172-1-LAB-01-out-110-10-27.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001172&Seq=002&Type=8"
        },
        {
            "title": "Phesgo賀雙妥 LD_外盒1200-600_001172-1-CTN-01-out-110-10-27.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001172&Seq=001&Type=8"
        }
    ]
}